Benzinga · Aug 24, 2026
Barclays Maintains Underweight on Dentsply Sirona, Raises Price Target to $11
Barclays analyst Glen Santangelo maintains Dentsply Sirona (NASDAQ:XRAY) with a Underweight and raises the price target from $9 to $11.
NASDAQ · XRAY
DENTSPLY SIRONA Inc.
Healthcare · Medical - Instruments & Supplies
$11.38
Down-$0.05 (-0.44%)
Updated Sep 5, 2026, 5:00 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.31B
- P/E ratio
- -2.62
- Dividend yield
- 5.62%
- 52-week range
- $9.41 – $14.86
- Volume
- 2.6M
- Avg. volume
- 3.53M
Price performance
XRAY price history
1M range · 21 trading sessions · Daily adjusted prices
XRAY closed at $11.38 after 21 trading sessions, down 6.11% for the selected period.
- Last close
- $11.38
- Period change
- -6.11%
- Period low
- $10.76
- Period high
- $12.12
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $11.29 | $11.53 | $11.195 | $11.38 | 2.6M |
| Sep 3, 2026 | $11.51 | $11.715 | $11.13 | $11.43 | 3.93M |
| Sep 2, 2026 | $10.89 | $11.55 | $10.83 | $11.29 | 4.61M |
| Sep 1, 2026 | $11.16 | $11.26 | $10.735 | $10.76 | 3.58M |
| Aug 31, 2026 | $11.185 | $11.225 | $10.89 | $11.17 | 4.43M |
| Aug 28, 2026 | $11.165 | $11.29 | $11.05 | $11.12 | 2.97M |
| Aug 27, 2026 | $10.80 | $11.26 | $10.80 | $11.04 | 3.56M |
| Aug 26, 2026 | $10.97 | $11.09 | $10.87 | $10.93 | 2.88M |
| Aug 25, 2026 | $10.81 | $10.99 | $10.605 | $10.97 | 3.11M |
| Aug 24, 2026 | $11.11 | $11.235 | $10.845 | $10.89 | 2.9M |
| Aug 21, 2026 | $10.845 | $11.0988 | $10.81 | $10.92 | 3.31M |
| Aug 20, 2026 | $11.05 | $11.15 | $10.75 | $10.78 | 3.47M |
| Aug 19, 2026 | $11.31 | $11.55 | $11.025 | $11.03 | 3.86M |
| Aug 18, 2026 | $11.24 | $11.41 | $11.08 | $11.11 | 4.07M |
| Aug 17, 2026 | $11.73 | $11.73 | $11.135 | $11.19 | 3.68M |
| Aug 14, 2026 | $11.50 | $11.88 | $11.46 | $11.59 | 2.71M |
| Aug 13, 2026 | $11.44 | $11.69 | $11.28 | $11.58 | 3.3M |
| Aug 12, 2026 | $11.48 | $11.7536 | $11.215 | $11.41 | 7.61M |
| Aug 11, 2026 | $11.63 | $11.96 | $11.56 | $11.61 | 4.14M |
| Aug 10, 2026 | $12.08 | $12.12 | $11.63 | $11.66 | 5.74M |
| Aug 7, 2026 | $13.36 | $13.578 | $12.01 | $12.12 | 8.57M |
Latest XRAY news
The latest Smart Investors Daily articles mentioning XRAY.
Stock researchCompany · Overview
XRAY research
Overview
Company profile and research snapshot.
Company profile
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $15.33
- Implied upside
- —
- Analysts
- 21
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | Barclays | Underweight | — |
| Jul 29, 2026 | Piper Sandler | Neutral | — |
| Jul 9, 2026 | BMO Capital | Market Perform | — |
| Jun 4, 2026 | Barclays | Underweight | — |
| May 7, 2026 | UBS | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 20, 2026
3 Unprofitable Stocks with Open Questions
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Yahoo · Aug 19, 2026
Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?
Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.
Yahoo · Aug 19, 2026
New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence
Wellspect HealthCare today announced the U.S. launch of the Surity™ Urinary Management System, a discreet at-home urine collection device designed to support people living with urinary incontinence and those who help care for them. This completes the full Surity™ portfolio in the U.S., following the introduction of the Surity™ Female and Male External Catheters earlier this year.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
